Endocyte and Nihon Medi-Physics (NMP) Enter Into Exclusive License Agreement to Develop and Commercialize Companion Imaging Diagnostic Etarfolatide for Cancer in Japan

By: Benzinga
Endocyte (Nasdaq: ECYT ), a biopharmaceutical company and leader in targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, and Nihon Medi-Physics (NMP), a market leader in the development, production and distribution of radiopharmaceuticals for nuclear medicine procedures in
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.